Oragenics Raises $16.5M, Repaid $3M Debt and Prepares Phase IIa Trial
Oragenics raised $16.5 million in 2025, repaid $3 million debt, reduced operating expenses by 11%, regained NYSE American compliance and moved drug manufacturing to FDA-cGMP facilities in North Carolina. In Q1 2026 it secured HREC approval in Australia, completed the first Phase IIa site initiation and engaged DUCK FLATS Pharma for U.S. IND readiness.
1. Annual Report Filing
Oragenics filed its Form 10-K for the fiscal year ended December 31, 2025, including audited financial statements and a shareholder update on key operational and clinical milestones achieved in 2025 and progress made in the first quarter of 2026.
2. Operational and Financial Milestones in 2025
During fiscal 2025 Oragenics regained NYSE American compliance, engaged a CRO for Phase IIa ONP-002 trials across three Australian sites, relocated drug manufacturing to Sterling Pharma's FDA-cGMP facility in North Carolina, and formalized an AI partnership with Receptor.AI. The company completed a $16.5 million capital raise, repaid a $3 million promissory note, and reduced operating expenses by 11%.
3. First Quarter 2026 Clinical Advances
In Q1 2026 the company secured Human Research Ethics Committee approval in Australia, completed the first site initiation visit for its Phase IIa ONP-002 trial, and advanced two additional sites through research governance reviews. It also engaged DUCK FLATS Pharma to support U.S. IND readiness and clinical trial design.
4. Strategic Priorities for 2026
Oragenics aims to enroll and dose patients in its Australian Phase IIa ONP-002 trial, file an IND with the U.S. Food and Drug Administration for a U.S. clinical program, and pursue strategic acquisitions to expand its central nervous system asset portfolio leveraging its intranasal delivery platform.